"ToleroCare has great potential to dramatically improve patients' recovery following major surgery, as well as to significantly reduce costs by shortening the time spent in hospital. With approximately 825,000 high-risk surgical procedures carried out each year in the US, and the high cost associated with hospital stays, ToleroCare is targeting a major market opportunity," said Steve Harris, Circassia's CEO. "Dopexamine provides Circassia with a further phase II clinical-stage development programme that fits well with our outsourced business model. By establishing a commercial-scale supply chain for dopexamine, we are well positioned to rapidly progress ToleroCare to market."
Circassia is a specialty biopharmaceutical company focused on the fields of allergy and critical care. The company has a highly experienced management team with a proven track record in product development and commercialization, and having successfully completed two fundraising rounds is backed by a syndicate of world-class venture capital and institutional investors, which includes Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.
Circassia's lead products target allergies utilizing the company's
proprietary T-cell epitope desensitization technology, ToleroMune(R). The
company is also developing its ToleroTrans(R) organ anti-rejection
technology, which uses a similar approach to down-regulate immune responses
in transplant patients. Circassia has a number of ongoing development
programmes, with the most advanced against cat-dander allergy in phase II
For more information please visit http://www.circassia.co.uk.
Steve Harris Rob Budge
CEO RJB Communications
Circassia Tel: +44(0)1865-7609
|SOURCE Circassia Ltd|
Copyright©2008 PR Newswire.
All rights reserved